Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Oberg

Showing results (31-40 of 302) with videos related to

Pageof 31
Sort By:
Henry Ford Hospital Medical Journal|January 1, 1992
Prospective screening in multiple endocrine neoplasia type 1B Skogseid, K Oberg
Nordisk Medicin|January 1, 1988
[Management of endocrine pancreatic tumors]B Eriksson, K Oberg
Journal of Internal Medicine|September 1, 1995
Experience with multiple endocrine neoplasia type 1 screeningB Skogseid, K Oberg
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 1999
Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlookB Eriksson, K Oberg
Lancet (London, England)|January 1, 1983
Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazoleK Oberg, H Lindström
Acta Oncologica (Stockholm, Sweden)|January 1, 1989
Medical treatment of neuroendocrine gut and pancreatic tumorsK Oberg, B Eriksson
British Journal of Haematology|October 1, 1991
The role of interferons in the management of carcinoid tumoursK Oberg, B Eriksson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2008
Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-upK Oberg, S Jelic,
Prosthetics and Orthotics International|April 1, 1982
An investigation of kinematic and kinetic variables for the description of prosthetic gait using the ENOCH systemK Oberg, H Lanshammar
Biotherapy (Dordrecht, Netherlands)|January 1, 1997
The incidence and clinical significance of antibodies to interferon-a in patients with solid tumorsK Oberg, G Alm
Pageof 31

Showing results (31-40 of 302) with videos related to

Sort By:
Pageof 31
Henry Ford Hospital Medical Journal|January 1, 1992
Prospective screening in multiple endocrine neoplasia type 1B Skogseid, K Oberg
Nordisk Medicin|January 1, 1988
[Management of endocrine pancreatic tumors]B Eriksson, K Oberg
Journal of Internal Medicine|September 1, 1995
Experience with multiple endocrine neoplasia type 1 screeningB Skogseid, K Oberg
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 1999
Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlookB Eriksson, K Oberg
Lancet (London, England)|January 1, 1983
Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazoleK Oberg, H Lindström
Acta Oncologica (Stockholm, Sweden)|January 1, 1989
Medical treatment of neuroendocrine gut and pancreatic tumorsK Oberg, B Eriksson
British Journal of Haematology|October 1, 1991
The role of interferons in the management of carcinoid tumoursK Oberg, B Eriksson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2008
Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-upK Oberg, S Jelic,
Prosthetics and Orthotics International|April 1, 1982
An investigation of kinematic and kinetic variables for the description of prosthetic gait using the ENOCH systemK Oberg, H Lanshammar
Biotherapy (Dordrecht, Netherlands)|January 1, 1997
The incidence and clinical significance of antibodies to interferon-a in patients with solid tumorsK Oberg, G Alm
Pageof 31